Thyreos develops prophylactic vaccines for neuroinvasive herpesvirus infections. It focuses on developing herpesvirus vaccines and vaccine vectors for the animal health herpesviruses such as bovine, feline, porcine, equine, and human health markets. The company was founded in 2020 and is based in Lincoln, Nebraska.
Latest Thyreos News
May 8, 2023
Thyreos , a vaccine company that is developing a novel vaccine platform that protects against a range of herpesviruses, has announced a $750,000 investment round led by Invest Nebraska with participation from other local angel investors in the animal health and veterinary space. “The rapid completion of our seed round allowed Thyreos to quickly advance the development of our first vaccine targets. That would not have been possible without the commitment of Invest Nebraska and our strategic investors," said Thyreos CEO, Eric Zeece. The Thyreos team includes co-founders Gary Pickard, Ph.D. professor in the School of Veterinary Medicine at the University of Nebraska-Lincoln, Ekaterina Heldwein, Ph.D. professor in the Department of Molecular Biology and Microbiology at Tufts University, Gregory Smith, Ph.D. professor in the department of Microbiology-Immunology at Northwestern University, and CEO Eric Zeece. The Thyreos R2 platform is a major breakthrough that allows for production of effective vaccines against many herpesviruses that infect a range of animals from livestock and companion animals to ourselves. The company’s roadmap includes the human-health market, but initial commercial opportunities are focused on the animal health space. The commercialization of the Thyreos vaccine technology platform will significantly improve the beef industry’s ability to protect against Infectious Bovine Rhinotracheitis (IBR), which is an economically significant respiratory disease caused by a herpesvirus. IBR has negative impacts beyond respiratory issues. It can also decrease milk production and fertility, and often leads to secondary bacterial infections, which is why an effective vaccine against bovine herpesvirus would be such an important breakthrough. Thyreos has joined The Combine , an agriculture technology incubator located on Nebraska Innovation Campus, a program run by Invest Nebraska in collaboration with the Nebraska Department of Economic Development. Current incubator companies also in the cattle industry include Corral Technologies, FarmAfield, and Platform Cattle. “We are pleased to be a part of the Combine. In addition to offering proximity to other emerging agri-food technologies and companies, the program provides us with unique resources and contacts that have helped Thyreos to validate market assumptions and advance product development efforts,” said Thyreos Co-Founder Gary Pickard. “Nebraska is the leader in not only beef production but also the technology and innovation that will define the next generation of cattle operations around the world. We are excited to play a small part in Thyreos," said Invest Nebraska CEO Dan Hoffman. Thyreos Contact:
Thyreos Frequently Asked Questions (FAQ)
When was Thyreos founded?
Thyreos was founded in 2020.
Where is Thyreos's headquarters?
Thyreos's headquarters is located at 2125 Transformation Drive, Lincoln.
What is Thyreos's latest funding round?
Thyreos's latest funding round is Grant - II.
How much did Thyreos raise?
Thyreos raised a total of $3.52M.
Who are the investors of Thyreos?
Investors of Thyreos include National Institutes of Health, U.S. Department of Agriculture, Combine AgriFood Incubator and Invest Nebraska.